À proposConditionsConfidentialitéContact
 
Actualisation
The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases

The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases

AD/PD™ on UNLOK
Date de sortie : 2025-05-14
© AD/PD™ on UNLOK
The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases - QR Code
LibreNew
2 épisodes
Audio
Écouter sur Apple Podcasts
LibreNew
2 épisodes
Audio
Écouter sur Apple Podcasts
Date de sortie : 2025-05-14
© AD/PD™ on UNLOK
L’épisode le plus récent
Varying Regulatory Philosophies and AD Approval Priorities, AD/PD™ Session Spotlight

Varying Regulatory Philosophies and AD Approval Priorities, AD/PD™ Session Spotlight

In this episode of AD/PD™ Session Spotlight, we delve into Forum Discussion 1, "Varying Regulatory Philosophies and AD Approval Priorities – USA, EU, Asia, and Other Parts of the World," a dynamic exchange exploring how regional regulatory approache
Durée : 18:03
Lecture
In this episode of AD/PD™ Session Spotlight, we delve into Forum Discussion 1, "Varying Regulatory Philosophies and AD Approval Priorities – USA, EU, Asia, and Other Parts of the World," a dynamic exchange exploring how regional regulatory approaches impact the development, approval, and accessibility of Alzheimer’s disease therapies.
Co-moderated by Agneta Nordberg (Sweden) and David Holtzman (USA), this discussion brings together insights from international regulatory and clinical experts: Naohiro Egawa (Japan), Tamara Shiner (Israel), Henrik Zetterberg (Sweden), and Pavel Balabanov (The Netherlands).
Key highlights include:
• The complex landscape of disease-modifying drug approvals, exemplified by the case of kinumab
• Contrasts in regulatory frameworks between the EMA, FDA, and Japan’s PMDA
• The evolving role of biomarkers in diagnosis and treatment selection
• Ongoing challenges in balancing risk, clinical utility, and access across diverse healthcare systems
This episode is a must-listen for global stakeholders in Alzheimer’s research, regulation, and clinical care, looking to navigate the nuances of regional policy and foster cross-border collaboration in advancing neurodegenerative disease treatments.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/
Id. d’épisode : 1000708583429
GUID : 88fd2ec3-c229-4b86-a998-d11d59177e08
Date de publication : 14/5/2025 à 10:15:55

Description

AD/PD™ is the leading international platform dedicated to exploring the latest breakthroughs and treatments in Alzheimer's, Parkinson’s, and related neurodegenerative diseases. The "AD/PD™ Session Spotlight" series is an AI-powered podcast that brings you key insights from the AD/PD™ Conference, with expert presentations and research discussions transformed into concise, easy-to-digest episodes.
Join us as we uncover the latest innovations, explore groundbreaking research, and discuss the future of neurodegenerative disease treatments and therapies.

Adresse du flux

https://anchor.fm/s/103d0f530/podcast/rss

Apple Podcasts : Avis des utilisateurs

Pas d'entrée